Production (Stage)
Xenon Pharmaceuticals Inc.
XENE
$29.75
-$0.74-2.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.71% | -46.81% | -29.57% | -22.05% | -14.87% |
| Total Depreciation and Amortization | 12.46% | 200.64% | -61.42% | 9.47% | 65.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 110.07% | -17.08% | 510.43% | 114.90% | 61.56% |
| Change in Net Operating Assets | -104.98% | 958.04% | 72.38% | 46.39% | -332.11% |
| Cash from Operations | -33.48% | -53.63% | -6.38% | 1.63% | -34.22% |
| Capital Expenditure | 77.13% | -903.85% | 50.83% | 29.02% | 91.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 180.35% | 141.42% | -95.33% | 273.67% | -188.07% |
| Cash from Investing | 179.90% | 141.08% | -96.33% | 296.81% | -192.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -96.26% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -96.26% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 82.56% | -570.33% | 118.75% | -156.27% | -722.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 70.97% | 12.27% | -240.23% | 1,669.31% | -831.43% |